# Polymeric Nanoparticles--Tools in a Drug Delivery System in Selected Cancer Therapies
## 6 Polymeric Nanoparticles in Glioblastoma Multiforme Therapy  
Glioblastoma multiforme (GBM) is a primary malignant brain tumor characterized by a high mortality rate [88; 89]. Combination of surgery, radiotherapy and local chemotherapy consisting of implantable drug formulation appears to be most promising methods for treatment [90]. However, a significant disadvantage of commonly used chemotherapeutics is the short half-life in blood circulation, leading to difficulty in transporting and releasing the drug at the proper pathological lesion [91]. PNPs, due to their diversity and the possibility of loading them with various drugs, are of major interest. Furthermore, they can be modified to penetrate the BBB and reach cancer cells [88]. The above factors are associated with improved penetration of the drug into the tumor, reduced side effects on healthy tissues and increased concentration of the drug in the pathologically altered area [88]. Several routes of PNP administration for GBM can be distinguished, i.e., focused ultrasound, which uses the ability to temporarily open the BBB; convection-enhanced delivery, based on delivering the drug to the brain region using pump systems; intranasally,  
\begin{table}
\begin{tabular}{c c c c c c} \hline \hline
**Identifier** & \begin{tabular}{c} **Drug Delivery** \\ **System** \\ \end{tabular}  & **Title** & **Cancer** & **Phase** & **Status** \\ \hline NCT03774680 & PNPs & \begin{tabular}{c} Targeted Polymeric Nanoparticle Loaded \\ With Cetuximab and Decorated With \\ Somatostatin Analogue to Colon Cancer \\ Neoadjuvant Chemoradiotherapy With \\ CRLX-101 and Capecitabine for \\ Rectal Cancer \\ An Early Phase Study of Abraxane \\ Combined With Phenelazine Sulfate in Patient \\ With Metastatic or Adcanced Breast Cancer \\ (Epi-PRIMED) \\ Abraxane® With or Without Mifepristone \\ for Advanced, Glucocorticoid \\ Receptor-Positive, Triple-Negative \\ Breast Cancer \\ Cryoablation, Atezolizumab/Nab-paclitaxel \\ \end{tabular}  & \begin{tabular}{c} Colon Cancer \\ \end{tabular}  & I & Unknown \\ NCT02010567 & PNPs & \begin{tabular}{c} N4-101 and Capecitabine for \\ Rectal Cancer \\ An Early Phase Study of Abraxane \\ Combined With Phenelazine Sulfate in Patient \\ With Metastatic or Adcanced Breast Cancer \\ (Epi-PRIMED) \\ Abraxane® With or Without Mifepristone \\ for Advanced, Glucocorticoid \\ Receptor-Positive, Triple-Negative \\ Breast Cancer \\ \end{tabular}  & Rectal Cancer & II & Terminated \\ NCT03505528 & Nab-paclitaxel & \begin{tabular}{c} Combined With Phenelazine Sulfate in Patient \\ With Metastatic or Adcanced Breast Cancer \\ (Epi-PRIMED) \\ Abraxane® With or Without Mifepristone \\ for Advanced, Glucocorticoid \\ Receptor-Positive, Triple-Negative \\ Breast Cancer \\ \end{tabular}  & Breast Cancer & I & Completed \\ NCT04249167 & Nab-paclitaxel & \
\begin{tabular}{c} Cryoablation, Atezolizumab/Nab-paclitaxel \\ for Locally Advanced or Metastatic Triple \\ Negative Breast Cancer \\ Paclitaxel Albumin-Stabilized Nanoparticle \\ Formulation in Treating Patients With \\ Recurrent or Persistent Ovarian Epithelial \\ Cancer, Fallopian Tube Cancer, or Primary \\ Peritoneal Cancer \\ Apatinib With Albumin-bound Paclitaxel in \\ Patients With Platinum-resistant Recurrent \\ Ovarian Cancer \\ CRLX101 in Combination With \\ bevacizumab for Recurrent \\ Ovarian/Tubal/Peritoneal Cancer \\ NCT00313599 & Nab-paclitaxel \\ NCT03719326 & Nab-paclitaxel &
\begin{tabular}{whereby the nanoparticles are absorbed through the olfactory pathways; and the use of polymeric hydrogels intracarainally (Figure 6) [92]. [PERSON] et al. [93] developed anti-EGFRIII-modified conjugated polymer nanoparticles. Poly [2-methoxy-5-(2-ethylhexyloxy)-\(p\)-phenylenevinylene] was used as the core. The developed system exhibited high reactive oxygen species generation ability under white-light irradiation.